BASF Beauty Care Solutions France SAS;Centre National de la Recherche Scientifique;Université Claude Bernard Lyon I
发明人:
BOUEZ, Charbel,GLEYZAL, Claudine,ORLY, Isabelle,ANDRE, Valérie,SOMMER, Pascal,REYMERMIER, Corinne,DAMOUR, Odile,PERRIER, Eric
申请号：
EP06831309.7
公开号：
EP1948128B1
申请日:
2006.10.26
申请国别(地区):
EP
年份:
2017
代理人:
摘要：
Use of a substance (I) modulating the expression and/or the activity of LOX having a sequence (SEQ ID No. 1: Not defined) and/or modulating the expression and/or the activity of NRAGE having a sequence (SEQ ID No. 2: Not defined) for making a composition to modulate the interaction between LOX and NRAGE proteins and to regulate the equilibrium between the phenomena of cell proliferation, differentiation and apoptosis, in particular in the cases where the interaction between LOX and NRAGE is absent or altered. Independent claims are included for: (1) an identification of an active ingredient that modulates the interaction between LOX and NRAGE, to improve the interaction between LOX and NRAGE when the interaction is absent or altered and to prevent or treat a state in which cellular equilibrium between proliferation, differentiation and apoptosis, is absent or altered, comprising contact of the active ingredient with living cells that are able to express the protein LOX having a sequence comprising (SEQ ID No. 1: Not defined) and/or protein NRAGE having a sequence comprising (SEQ ID No. 2: Not defined) and expression analysis of LOX and/or NRAGE, to identify an active ingredient modulating the expression and/or the activity of LOX and/or NRAGE to improve cellular equilibrium between proliferation, differentiation and apoptosis； (2) preparation of a composition comprising identification of the active ingredient using the identification method and mixing the active ingredient with an excipient to form a cosmetic, neutraceutic, dermopharmaceutic or pharmaceutical composition to prevent or treat a state in which cellular equilibrium between proliferation, differentiation and apoptosis is absent or altered； and (3) localization method of NRAGE, comprising use of anti-NRAGE antibody to detect and locate the presence of NRAGE, in a rebuilt skin model comprising the keratinocytes, or a skin section, preferably a skin section from a person whose epidermis presents a state in
